JPM's M&A Monday frenzy; Ozempic selected for IRA negotiations; Pfizer says...
Welcome back to the new and improved Endpoints Weekly! This week we’ll be recapping the JP Morgan Healthcare Conference, IRA price negotiations, Pfizer’s plans to get back on track, and more. Thanks to...
View ArticleAnother US biotech emerges with drug candidate from China-based Keymed
The China-to-US experimental medicine pipeline is ballooning: yet another US-based biotech formed around a candidate from China's Keymed Biosciences on Monday. Life sciences investment firm RTW has set...
View ArticleSionna and Odyssey end JPM week with IPO filings
Sionna Therapeutics and Odyssey Therapeutics have joined Metsera and Maze in an attempt to go public via the still-rocky IPO route. The biotechs, focused on cystic fibrosis and immunology,...
View ArticleExiting Medicare director expects current law to guide next price negotiations
Meena Seshamani believes the landmark Inflation Reduction Act will “lay the foundation” for future drug price negotiations under the new Trump administration. Seshamani, the former Medicare director...
View ArticleWith support from NFL owner Jeffrey Lurie, Icelandic biotech closes Series A...
A father-and-son biotech with ties to Iceland and Philadelphia has put together a €26.5 million Series A to develop oral treatments for Alzheimer’s disease and other neurodegenerative conditions....
View ArticleAscentage estimates $133M in proceeds as it plans dual listing
Ascentage Pharma's plans for a dual listing in the US could load its coffers with about $133 million in net proceeds, the commercial drugmaker said in a Tuesday SEC filing. ...
View ArticleFDA puts Atara’s INDs on hold after rejection; Ascletis' safety data for...
Plus, news about Amylyx and Sanofi: FDA places hold on Atara Biotherapeutics’ active INDs: The holds affect the T cell therapy that the agency rejected last week as well as another program called...
View ArticleChina's drug development explosion forces a US biotech reckoning
In 2019, Stanford University professor Irv Weissman and a colleague published a paper that represented a new way to target some aggressive cancers. Shortly after, they did what many researchers do when...
View ArticleWhat to make of UnitedHealth Group’s rebate move
In its first earnings since the murder of UnitedHealthcare CEO Brian Thompson, UnitedHealth Group made a move that caught industry insiders’ attention. The healthcare giant said its pharmacy benefit...
View ArticleSanofi says no supply interruptions after landing FDA warning letter for US site
A new FDA warning letter for French pharmaceutical company Sanofi cited a handful of issues at its biologics factory in Massachusetts. The letter, published on Tuesday, was handed to Sanofi on ...
View ArticleJ&J's Spravato wins expanded label for depression as singular treatment
Johnson & Johnson’s Spravato nasal spray received a label expansion on Tuesday, now approved as a standalone treatment for major depressive disorder in adults after two oral antidepressants fail,...
View ArticleRenewed mifepristone fight will test Trump’s abortion stance
A revived legal challenge to the abortion pill mifepristone will be an early test for President Donald Trump’s administration and his appetite for further weighing in on reproductive health access in...
View ArticleUS withdrawal from WHO could jeopardize information sharing
The Trump administration’s decision to withdraw from the World Health Organization could complicate US access to health information that’s vital for pharmaceutical companies, academics said Tuesday....
View ArticleOncology biotech ArriVent does another China ADC deal, this time with Lepu...
Bing Yao's ArriVent BioPharma has inked another licensing deal with a Chinese biopharma. The late-stage oncology biotech is picking up a new antibody-drug conjugate from Shanghai-based Lepu Biopharma,...
View ArticleGLP-1s can cut the risk of Alzheimer’s. What does that mean for Novo Nordisk?
A new study found that patients taking GLP-1s to treat type 2 diabetes have a lower risk of developing Alzheimer’s disease, potentially opening the door to another lucrative category for Novo Nordisk....
View ArticleRegeneron CSO George Yancopoulos on AI's hype and potential
SAN FRANCISCO — Just over 20 years ago, the people of California voted to spend billions of dollars on an exciting new idea to remake medicine. Agreeing to put $3 billion toward ...
View ArticleInhibrx’s early colorectal cancer data clouded by patient death
One of Inhibrx Biosciences’ antibody candidates has shown encouraging early efficacy in colorectal cancer. But its safety is under scrutiny after a patient enrolled in the Phase 1 trial died. The...
View ArticleJ&J’s Spravato hit $1B in revenue in 2024
Johnson & Johnson’s burgeoning depression treatment Spravato eclipsed $1 billion in revenue in 2024 as the pharma’s neuroscience pipeline comes into view. In its fourth-quarter earnings on...
View ArticleShanghai Bao, Sichuan Biokin file IPOs in Hong Kong; Disc's $200M offering
Plus, news about Rivus and Crown Labs: Two Chinese biotechs file for stock listings in Hong Kong: Shanghai Bao Pharmaceuticals and Sichuan Biokin Pharmaceutical join a queue of Chinese drug developers...
View Article